Rockwell Medical, Inc.

RMTI

US7743743004

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
1.51 ^USD	+1.34%		+2.03%	-20.11%

Apr. 17	Rockwell Medical Continues to Expand Its Distribution Capabilities in Western United States	CI
Apr. 04	Rockwell Medical Expands Global Distribution in the Dominican Republic and Bermuda	CI

Rockwell Medical, Inc. Appoints John P. McLaughlin Chairman of the Board of Directors, Effective Immediately

October 31, 2019 at 04:30 pm EDT

Rockwell Medical, Inc. announced the appointment of John P. McLaughlin as its Chairman of the Board, effective immediately. Mr. McLaughlin, who joined the Board on September 5, 2019, succeeds Benjamin Wolin, who will remain on the Board of Directors.

Latest news about Rockwell Medical, Inc.

Rockwell Medical Continues to Expand Its Distribution Capabilities in Western United States	Apr. 17	CI
Rockwell Medical Expands Global Distribution in the Dominican Republic and Bermuda	Apr. 04	CI
HC Wainwright Cuts Price Target on Rockwell Medical to $9 From $11, Keeps Buy Rating	Mar. 25	MT
Transcript : Rockwell Medical, Inc., Q4 2023 Earnings Call, Mar 21, 2024	Mar. 21
(RMTI) ROCKWELL MEDICAL Expects Fiscal Year 2024 Revenue Range $84M - $88M	Mar. 21	MT
Earnings Flash (RMTI) ROCKWELL MEDICAL Posts Q4 Revenue $22.1M	Mar. 21	MT
Rockwell Medical, Inc. Provides Earnings Guidance for the Year 2024	Mar. 21	CI
Rockwell Medical, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 21	CI
Earnings Flash (RMTI) ROCKWELL MEDICAL Reports Q4 EPS $0.02	Mar. 21	MT
Rockwell Medical, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 21	CI
Rockwell Medical, Inc. Provides Earnings Guidance for Fourth Quarter and Full-Year 2023	Jan. 08	CI
Rockwell Medical Amends Loan and Security Agreement with Innovatus Life Sciences Lending Fund	Jan. 08	CI
Transcript : Rockwell Medical, Inc., Q3 2023 Earnings Call, Nov 14, 2023	Nov. 14
Earnings Flash (RMTI) ROCKWELL MEDICAL Reports Q3 Revenue $23.8M	Nov. 14	MT
Rockwell Medical, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Rockwell Medical, Inc. Provides Financial Guidance for the Year 2023	Nov. 14	CI
Rockwell Medical, Inc. Appoints Jesse Neri as Senior Vice President, Finance	23-10-18	CI
Rockwell Medical, Inc. Appoints Joan Lau, Ph.D. to the Company's Board of Directors	23-10-17	CI
Maxim Initiates Coverage on Rockwell Medical with Buy Rating, $5 Price Target	23-10-05	MT
Rockwell Medical to be the Preferred Supplier of Hemodialysis Concentrates, Accessories to Centers for Dialysis Care	23-10-03	MT
Rockwell Medical Signs Multi-Year Product Purchase Deal With Centers for Dialysis Care; Shares Climb Premarket	23-10-03	MT
Rockwell Medical Enters into 3-Year Product Purchase Agreement with Centers for Dialysis Care	23-10-03	CI
Rockwell Medical to Supply Materials to Sanderling Renal Services Facilities	23-09-28	MT
Rockwell Medical Enters into 3-Year Product Purchase Agreement with Sanderling Renal Services	23-09-28	CI
Sector Update: Health Care Stocks Tick Lower Thursday Morning	23-09-21	MT

Chart Rockwell Medical, Inc.

Duration

Period

More charts

Company Profile

Rockwell Medical, Inc. is a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers around the world. It operates in the hemodialysis market, which involves the manufacture, sale and distribution of hemodialysis products to hemodialysis clinics, including pharmaceuticals, dialysis concentrates, dialysis kits and other ancillary products used in the dialysis process. It is the supplier of life-sustaining hemodialysis concentrates products to dialysis clinics. Its hemodialysis concentrates products are used to sustain a patient's life by removing toxins and balancing electrolytes in a dialysis patientâs bloodstream. Its first two branded products from its ferric pyrophosphate citrate (FPC) platform, Triferic (dialysate) and Triferic AVNU, are indicated to maintain hemoglobin in patients undergoing hemodialysis. It offers dry and liquid citric acid, acetic acid, and bicarbonate hemodialysis products.

Sector

Pharmaceuticals

Calendar

2024-05-14 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Rockwell Medical, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

1.49 USD

Average target price

7 USD

Spread / Average Target

+369.80%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ROCKWELL MEDICAL, INC.	-20.11%	43.75M
NOVO NORDISK A/S	+24.17%	562B
JOHNSON & JOHNSON	-6.33%	358B
MERCK & CO., INC.	+19.90%	322B
ABBVIE INC.	+7.95%	297B
ASTRAZENECA PLC	+13.45%	219B
NOVARTIS AG	+6.04%	199B
ROCHE HOLDING AG	-10.51%	196B
PFIZER, INC.	-12.26%	149B
AMGEN INC.	-6.47%	146B

Other Pharmaceuticals